Why Now? The New Paradigm and Rising Role of Nuclear Medicine in Alzheimer’s Disease
With the field’s increasing understanding of and ability to manipulate the complex networks of amyloid and tau that drive Alzheimer’s disease (AD), the value of directly visualizing their activity is exponentially rising. The implications for the future of AD diagnosis coupled with the rising potential that disease modifying therapies will reach routine clinical use corresponds to a potentially dramatic increase in the need for nuclear medicine (NM) in this field. This symposium, originally held in conjunction with the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, is designed to highlight the perspectives of noted experts on just how the role of NM is evolving in AD. Using recent data and clinical experience, the faculty will guide learners through recommended NM practices and reinforce the foundational knowledge required to adopt the skills needed for deeper involvement in AD management going forward.
This activity is intended for nuclear medicine physicians, radiologists, neurologists, technologists, and other healthcare professionals involved in the diagnosis and long-term management of patients with AD.
Upon completion of the educational activity, participants should be able to:
- Evaluate the evolving role of neurobiology in the modern management of AD to ascertain how and where NM will be most valuable in the coming years.
- Recognize the variable uses of and key techniques involved in evaluation of amyloid PET for diagnosis and therapeutic management of AD to determine how and for whom this test is best utilized.
- Appraise the rising importance of tau PET imaging for AD prognosis and its role in therapeutic trials to determine its potential clinical utility.
- Identify the current status of and investigated outcomes with new and emerging amyloid-targeting disease modifying therapies designed to treat AD to determine their potential role in clinical practice.
Sharon Cohen, MD, FRCPC (Moderator)
Behavioral Neurologist, Medical Director, and Site PI
Toronto Memory Program
Gil Rabinovici, MD
Edward Fein & Pearl Landrith Distinguished Professor
Director, UCSF Alzheimer’s Disease Research Center
Departments of Neurology, Radiology and Biomedical Imaging
University of California, San Francisco
James Brewer, MD, PhD
Chair, Department of Neurosciences
Professor, Departments of Neurosciences and Radiology
Director, Shiley-Marcos Alzheimer's Disease Research Center
Director, Alzheimer's Disease Cooperative Study Imaging Core
University of California, San Diego
This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
MER designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Relevant Financial Relationships
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
Planners’ and Managers’ Disclosure
MER planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.
Dr Cohen reported the following financial relationships:
- Research Support: AgeneBio, Alector, Alnylam, Anavex, Biogen, Cassava, Eisai, Eli Lilly, Green Valley, Janssen, Novo Nordisk, RetiSpec, Roche, UCB, Vielight
- Consulting Fees: Alnylam, Biogen, Cognivue, Cogstate, Eisai, Eli Lilly, INmune Bio, Novo Nordisk, ProMIS Neurosciences, RetiSpec, Roche
Dr Brewer reported the following financial relationships:
- Ownership Interest: ACLIP, CorTechsAi, Enkephalos, Impact Biomedicines
Dr Rabinovici reported the following financial relationships:
- Research Support: Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, Life Molecular Imaging, NIH, Tau Consortium
- Consulting Fees: Axon Neurosciences, Eisai Roche, GE Healthcare, Genentech, Merck
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from Lilly.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance